MX2024008389A - Polipéptidos de unión a células t gamma delta, y usos de los mismos - Google Patents

Polipéptidos de unión a células t gamma delta, y usos de los mismos

Info

Publication number
MX2024008389A
MX2024008389A MX2024008389A MX2024008389A MX2024008389A MX 2024008389 A MX2024008389 A MX 2024008389A MX 2024008389 A MX2024008389 A MX 2024008389A MX 2024008389 A MX2024008389 A MX 2024008389A MX 2024008389 A MX2024008389 A MX 2024008389A
Authority
MX
Mexico
Prior art keywords
cell
binding polypeptides
gamma delta
delta
gamma
Prior art date
Application number
MX2024008389A
Other languages
English (en)
Spanish (es)
Inventor
Bryan R Becklund
Kyle S Jones
Kaitlyn N Robinson
Andrew M Eckles
John C Timmer
Brendan P Eckelman
Original Assignee
Inhibrx Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inhibrx Biosciences Inc filed Critical Inhibrx Biosciences Inc
Publication of MX2024008389A publication Critical patent/MX2024008389A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MX2024008389A 2022-01-05 2024-07-02 Polipéptidos de unión a células t gamma delta, y usos de los mismos MX2024008389A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263296774P 2022-01-05 2022-01-05
US202263417926P 2022-10-20 2022-10-20
PCT/US2023/060074 WO2023133394A1 (en) 2022-01-05 2023-01-04 Gamma delta t-cell-binding polypeptides and uses thereof

Publications (1)

Publication Number Publication Date
MX2024008389A true MX2024008389A (es) 2024-12-06

Family

ID=85199216

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024008389A MX2024008389A (es) 2022-01-05 2024-07-02 Polipéptidos de unión a células t gamma delta, y usos de los mismos

Country Status (11)

Country Link
US (1) US20250066477A1 (enExample)
EP (1) EP4460521A1 (enExample)
JP (1) JP2025504363A (enExample)
KR (1) KR20240130130A (enExample)
CN (1) CN119213028A (enExample)
AU (1) AU2023205911A1 (enExample)
CA (1) CA3242658A1 (enExample)
IL (1) IL314073A (enExample)
MX (1) MX2024008389A (enExample)
TW (1) TW202334233A (enExample)
WO (1) WO2023133394A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025140683A1 (zh) * 2023-12-29 2025-07-03 北京鼎成肽源生物技术有限公司 表达趋化因子10和白介素15的工程化免疫细胞
WO2025144974A1 (en) * 2023-12-29 2025-07-03 Absci Corporation Half-life extending fc domain variants and uses thereof
WO2026006719A1 (en) * 2024-06-28 2026-01-02 IN8bio, Inc. Multifunctional molecules and methods of treatment

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
DK1034298T3 (da) 1997-12-05 2012-01-30 Scripps Research Inst Humanisering af murint antistof
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
CA2541651C (en) 2003-10-22 2011-05-24 Keck Graduate Institute Methods of synthesizing heteromultimeric polypeptides in yeast using a haploid mating strategy
EP1740615B1 (en) 2004-03-31 2014-11-05 Genentech, Inc. Humanized anti-tgf-beta antibodies
DK3129404T3 (da) * 2014-04-10 2026-04-20 Lava Therapeutics N V Immunglobuliner, der binder humane vgamma9vdelta2-t-cellereceptorer
GB201707048D0 (en) * 2017-05-03 2017-06-14 King S College London Expansion of gamma delta cells, compositions, and methods of use thereof
JP7611820B2 (ja) * 2018-10-11 2025-01-10 インヒブルクス バイオサイエンシズ インコーポレイテッド Ｄｌｌ３シングルドメイン抗体およびその治療用組成物
CN113993893A (zh) * 2019-02-01 2022-01-28 拉法医疗有限公司 新cd40结合抗体
BR112021020999A2 (pt) * 2019-05-04 2021-12-14 Inhibrx Inc Polipeptídeos de ligação à clec12a e usos dos mesmos
MX2022006547A (es) * 2019-12-03 2022-08-19 Adicet Bio Inc Métodos para la expansión de poblaciones de células t gamma delta con agentes multivalentes y composiciones de estas.
CN115485369A (zh) * 2020-03-03 2022-12-16 詹森生物科技公司 γδT细胞及其用途

Also Published As

Publication number Publication date
TW202334233A (zh) 2023-09-01
WO2023133394A1 (en) 2023-07-13
US20250066477A1 (en) 2025-02-27
IL314073A (en) 2024-09-01
CA3242658A1 (en) 2023-07-13
JP2025504363A (ja) 2025-02-12
CN119213028A (zh) 2024-12-27
KR20240130130A (ko) 2024-08-28
EP4460521A1 (en) 2024-11-13
AU2023205911A1 (en) 2024-07-11

Similar Documents

Publication Publication Date Title
MX2024008389A (es) Polipéptidos de unión a células t gamma delta, y usos de los mismos
CO2021016015A2 (es) Inhibidores de tead y usos de los mismos referencia cruzada a solicitudes relacionadas
CO2020014009A2 (es) Inhibidores de mcl-1
MX2019003254A (es) Compuestos y metodos para la modulacion de ido y tdo, e indicaciones de estos.
BR112021012037A2 (pt) Molécula anti-pd-1/il-7 bifuncional
ECSP18066138A (es) Inhibidores de la proteína quinasa 1 que interactua con el receptor
CL2021001627A1 (es) Molécula bifuncional anti-pd-1/sirpa
CL2023000701A1 (es) Anticuerpos que se unen a il1rap y usos de los mismos
BR112021021048A2 (pt) Polipeptídeos que se ligam a cd33 e seus usos
CO2020012347A2 (es) Anticuerpos anti-hla-g y usos de los mismos.
MX2020014243A (es) Neoantigenos y usos de los mismos.
UY37258A (es) AGENTES REVERSORES DE UNIÓN PARA ANTICUERPOS ANTI-FACTOR XI/XIa Y SUS USOS
MX2019015018A (es) Composiciones que comprenden curones y usos de los mismos.
BR112021020999A2 (pt) Polipeptídeos de ligação à clec12a e usos dos mesmos
MX2021006977A (es) Anellosomas y metodos de uso.
MX2018009405A (es) Sintesis y composicion de bibliotecas de rapafucina.
CL2020000101A1 (es) Compuestos de cetonas bicíclicas y métodos de uso de los mismos.
CL2022001456A1 (es) Tiofenocarboxamidas sustituidas y sus derivados
MX2020006001A (es) Composicion para el cuidado personal.
CO2022009510A2 (es) Compuestos activos frente a receptores nucleares
CO2023010689A2 (es) Anticuerpos y usos de estos
MX2021014961A (es) Compuestos triciclicos y su uso.
CL2018001781A1 (es) Amidas heterocíclicas nematicidas
PE20110883A1 (es) Sello de doble placa
CL2023001269A1 (es) Construcción polipeptídica que se une a cd3; composiciòn farmacéutica; y su uso.